Cancer is a disease caused by genomic changes in the cells of our body. These changes, called mutations, can be harmful, beneficial, or have no effect. Harmful mutations can cause normal cells to grow and divide uncontrollably, leading to cancer.
Genomic profiling sheds light on the combination of mutations that makes each patient’s cancer unique. This information can be used to personalize treatment for every patient.
LiquidHALLMARK® provides Swift , Simple and Sensitive Genomic Profiling
Genomic testing provides additional information to your provider that helps to personalize treatment according to your tumor’s genomic profile. Your genomic profile can also be used to match you to suitable clinical trials where new medicines are being developed, as well as track mutation changes in your tumor.
LiquidHALLMARK is a liquid biopsy genomic test that reveals important information about a tumor from a single blood draw. This information is what is known as a tumor’s genomic profile. LiquidHALLMARK provides your doctor with information to develop a personalized treatment plan at the time of diagnosis based on your tumor genomic profile. Testing can also be utilized to monitor your treatment response and/or changes within a tumor.
LiquidHALLMARK® is covered for most Medicare and commercial healthcare plans when clinical criteria is met.
Lucence is committed to making sure that cost is not a barrier for patients to access LiquidHALLMARK® liquid biopsy testing.
For billing questions or ﬁnancial assistance, please contact a Lucence Reimbursement Advisor
*For US Residents OnlyView Billing FAQs